FDA Signals New Testosterone Pathway - Takeaways - MDSpire

FDA Signals New Testosterone Pathway

Agency invites sponsors to pursue low libido indication

Share

1

The FDA is encouraging sponsors of testosterone replacement therapy to pursue a new indication for low libido in men with idiopathic hypogonadism.
2

Currently, TRT products are approved only for men with hypogonadism due to established structural or genetic causes.
3

The FDA's review indicated that TRT may be safe and effective for men with decreased libido linked to idiopathic hypogonadism.
4

Sponsors are advised to contact the FDA by April 30 to discuss submission requirements for supplemental applications.
5

Any new indication approval will require substantial evidence of effectiveness and a favorable risk-benefit assessment.